an Heart Therapeutics Appoints Charlotte Arnold As Chief Corporate Affairs Officer

Sep 28, 2023•about 2 years ago

Position

Chief Corporate Affairs Officer

Company

AnHeart Therapeutics

Charlotte Arnold

New YorkBiopharmaTherapeuticsPharmaceuticalBiotechnologyHealth Care

Description

NEW YORK–– AnHeart Therapeutics , a global clinical-stage biopharmaceutical company developing novel precision therapies for people with cancer, today announced the appointment of Charlotte Arnold as Chief Corporate Affairs Officer.

Company Information

Company

AnHeart Therapeutics

Location

New York, New York, United States

About

AnHeart Therapeutics Ltd. is a global clinical-stage biopharmaceutical company developing novel precision therapies for people with cancer. Their lead asset, taletrectinib, is a next-generation ROS1 inhibitor with potentially best-in-class profile aiming to overcome the limitations of existing therapies.

Related People

Executive Insights

Based on hiring data

New executive impact window

87% of new executives make significant technology decisions within first 100 days

Budget influence

C-level executives control 73% of technology spending decisions

Transformation catalyst

65% of new senior hires launch digital transformation initiatives

Vendor review timeline

New executives typically review existing vendors within 6 months

an Heart Therapeutics Appoints Charlotte Arnold As Chief Corporate Affairs Officer

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Related People

Executive Insights

Company Information